Due to the high rate of EGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease.
Steven F. Powell, MD
Advertisement
Articles by Steven F. Powell, MD
Advertisement
Latest Updated Articles
A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited TissuePublished: October 17th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How ADCs and BiTEs Are Propelling Change in Lung Cancer
2
FDA Accepts NDA for Zidesamtinib in Pretreated Advanced ROS1+ NSCLC
3
Less Than Half of Incarcerated Population Receives Recommended Cancer Care
4
Sequencing After Amivantamab + Lazertinib and Cumulative Toxicity
5
